Paromomycin in the treatment of leishmaniasis
- 30 April 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 17 (5) , 787-794
- https://doi.org/10.1517/13543784.17.5.787
Abstract
(2008). Paromomycin in the treatment of leishmaniasis. Expert Opinion on Investigational Drugs: Vol. 17, No. 5, pp. 787-794. doi: 10.1517/13543784.17.5.787Keywords
This publication has 30 references indexed in Scilit:
- L’amphotéricine B liposomale en prophylaxie secondaire chez les patients VIH+ atteints de leishmaniose viscérale : à propos de cinq casPathologie Biologie, 2004
- Post-kala-azar dermal leishmaniasisThe Lancet Infectious Diseases, 2003
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Response to Interferon‐γ plus Pentavalent Antimony in Indian Visceral LeishmaniasisThe Journal of Infectious Diseases, 1997
- Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)Journal of Infection, 1996
- POST‐KALA‐AZAR DERMAL LEISHMANIASISInternational Journal of Dermatology, 1995
- Epidemic Visceral Leishmaniasis in Sudan: A Randomized Trial of Aminosidine plus Sodium Stibogluconate versus Sodium Stibogluconate AloneThe Journal of Infectious Diseases, 1993
- Amphotericin B for second-line treatment of Indian kala-azarThe Lancet, 1991
- Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised studyBMJ, 1988
- The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasisPathogens and Global Health, 1968